George D. Demetri, M.D.

Professor of Medicine at Harvard Medical School, Director of the Center for Sarcoma and Bone Oncology, and physician at the Dana-Farber Cancer Institute

George is a member of our Board of Directors and a scientific advisor to the company. He is a Professor of Medicine at Harvard Medical School, Director of the Center for Sarcoma and Bone Oncology, and a physician at the Dana-Farber Cancer Institute (DCFI). George and the multidisciplinary team at Dana-Farber/Harvard Cancer Center have developed one of the largest centers of excellence for research and care of sarcoma patients, focusing on the development of novel therapies. His research and clinical interests have centered on mechanism-based drug development for solid tumors, with a particular emphasis on molecularly defined subsets of sarcomas, such as gastrointestinal stromal tumors. He has contributed to the development of numerous kinase cancer therapies, including Gleevec (imatinib), Sutent (sunitinib), Sprycel (dasatinib), Zelboraf (vemurafenib) and Votrient (pazopanib) as well as other new targeted therapies in development. George serves as chair of the medical advisory board for the Sarcoma Foundation of America, as well as several scientific and editorial advisory boards. With an interest in internet-based patient support, he serves on the Medical Advisory Board of American Society of Clinical Oncology’s CancerNet and CancerCommons.org. George has an undergraduate degree in biochemistry from Harvard University and an M.D. from Stanford University School of Medicine, completed his residency in internal medicine at the University of Washington Hospitals in Seattle and completed a fellowship in medical oncology at DCFI.

Giulio Draetta, M.D., Ph.D.

Director of the Institute for Applied Cancer Science at MD Anderson Cancer Center and Professor of Molecular and Cellular Oncology

Giulio is one of our scientific advisors. He is currently the director of the Institute for Applied Cancer Science at MD Anderson Cancer Center and Professor of Molecular and Cellular Oncology. Prior to joining MD Anderson, Giulio was chief research business development officer and deputy director of the Belfer Institute for Applied Cancer Science at Dana-Farber Cancer Institute. He has also served as head of oncology drug discovery at Pharmacia and Merck, where he focused on the discovery and development of inhibitors of receptor tyrosine kinase signaling, cell division cycle inhibitors, novel cytotoxics, developmental pathway inhibitors, and epigenetics drugs. He was co-founder and vice president of research for Mitotix and co-founded Karyopharm, Inc. During his time in academia, he served as an investigator at the Cold Spring Harbor Laboratory, the European Molecular Biology Laboratory in Heidelberg, Germany and at the European Institute of Oncology. He spearheaded fundamental research in the biology of the eukaryotic cell division cycle and of DNA damage induced checkpoints. Giulio received his medical and post-graduate degrees from the University of Naples Medical School, Italy.

Brian Druker, M.D.

Director of the Oregon Health & Science University Knight Cancer Institute and JELD-WEN Chair of Leukemia Research

Brian is one of our scientific founders and a scientific advisor to the company. He is an internationally respected researcher. Along with our other scientific founders, Nick Lydon, Ph.D., and Charles L. Sawyers, M.D., he was the recipient of the 2009 Lasker-DeBakey Award for Clinical Medical Research for his groundbreaking work with Gleevec® (imatinib), a targeted kinase inhibitor that transformed chronic myeloid leukemia from a fatal cancer into a manageable disease. Currently, Brian serves as the director of the Oregon Health & Science University Knight Cancer Institute and is the JELD-WEN Chair of Leukemia Research. He is a member of the National Academy of Sciences and a Howard Hughes Medical Institute Investigator. Brian conducted the first clinical studies of Gleevec, demonstrating that the drug could effectively return blood cell counts to normal in CML patients, with only minor side effects. Brian is currently focused on developing effective treatments for patients whose leukemia eventually recurs while taking Gleevec. He is the recipient of a Lifetime Achievement Award from the Leukemia and Lymphoma Society, the Medal of Honor from the American Cancer Society and many other awards. Brian received his M.D. from the University of California School of Medicine at San Diego, completed his residency in internal medicine at Washington University in St. Louis and performed his oncology fellowship at Harvard Medical School’s Dana-Farber Cancer Institute.

Marc Lang, Ph.D.

former Executive Director of the Medicinal Chemistry Unit for Oncology at Novartis

Marc is one of our scientific advisors. He has more than 30 years of experience in medicinal chemistry from various fields of research related to antibiotics, antivirals and oncology. Until recently, he was Executive Director of the Medicinal Chemistry Unit for Oncology at Novartis in Basel, Switzerland, and a member of the Global Oncology Decision Board at Novartis Institute for Biomedical Research. During his career, he contributed personally to three compounds currently on the market: Femara®(aromatase inhibitor), Reyataz® (HIV-protease inhibitor), Tasigna® (Bcr/Abl kinase inhibitor); and several promising compounds in clinical trials. Marc holds a Ph.D. in Chemistry from the University of Strasbourg and was a postdoctoral fellow at the Woodward Research Institute in Basel.

Scott Lowe, Ph.D.

Member of the Cancer Biology and Genetics Program at Memorial Sloan Kettering Institute Cancer Center and Chair of the Geoffrey Beene Cancer Research Center

Scott is one of our founders and scientific advisors. He is a member of the Cancer Biology and Genetics Program at Memorial Sloan Kettering Cancer Center (MSKCC), where he serves as the associate director for Basic Cancer Research. He is also chair of the Geoffrey Beene Cancer Research Center and a Howard Hughes Medical Institute Investigator. Dr. Lowe’s current research is based on the premise that the path of cancer evolution dictates a tumor’s subsequent response to therapy and creates unique vulnerabilities that represent therapeutic opportunities. His laboratory applies mouse models, RNA interference and cancer genomics in a coordinated effort to gain a more comprehensive understanding of tumor suppressor networks and identify cancer maintenance genes that will be useful therapeutic targets relevant to specific cancer genotypes. His earlier research made important contributions to our understanding of the p53 tumor suppressor pathway, as well as the processes of multi-step carcinogenesis, cellular senescence, and tumor-cell drug resistance. Dr. Lowe’s work has been recognized by several awards, including a Sydney Kimmel Foundation Scholar Award, a Rita Allen Foundation Scholar Award, the AACR Outstanding Investigator Award, AACR-NFCR Professorship in Basic Cancer Research, Alfred G. Knudsen Award in Cancer Genetics, and the Paul Marks Prize for Cancer Research. He received a B.S. from the University of Wisconsin-Madison and received his Ph.D. at the Massachusetts Institute of Technology.

Nick Lydon, Ph.D.

Founder, Granite Biopharma LLC

Nick is one of our scientific founders and a member of our Board of Directors. He is a renowned expert in the field of kinase drug discovery and development for cancer. In 2009, Nick and our other scientific founders, Brian Druker, M.D., and Charles L. Sawyers, M.D., were awarded the Lasker-DeBakey Award for Clinical Medical Research for their role in the discovery and development of Gleevec® (imatinib), a targeted kinase inhibitor that transformed chronic myeloid leukemia from a fatal cancer into a manageable disease. Dr. Lydon founded and currently runs the consulting firm Granite Biopharma LLC. He previously served as vice president, Small Molecule Drug Discovery at Amgen Inc. Prior to Amgen, he was the CEO and founder of Kinetix Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of selective protein kinase inhibitors. Amgen acquired Kinetix in 2000. Prior to Kinetix, Nick worked at CIBA-GEIGY, in Basel, Switzerland, where he was responsible for the protein kinase inhibitor program, including the discovery and preclinical development of Gleevec. He began his pharmaceutical career at Schering-Plough Corp., where his research involved studies on recombinant interferons. Nick has been awarded the Japan Prizes for his work on Gleevec. Other awards include the Warren Alpert Foundation Prize, the AACR-Bruce F. Cain Memorial Award and the Charles F. Kettering Prize from the General Motors Cancer Research Foundation. He earned a BS in biochemistry and zoology from the University of Leeds, England, and received his Ph.D. in biochemistry from the Medical Sciences Institute, University of Dundee, Scotland.

Charles L. Sawyers, M.D.

Director, Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center

Charles is one of our scientific founders and a scientific advisor to the company. He is a Howard Hughes Medical Institute Investigator and director of the Human Oncology and Pathogenesis Program at Memorial Sloan-Kettering Cancer Center (MSKCC). Along with our other scientific founders, Nick Lydon, Ph.D., and Brian Druker, M.D., he was the recipient of the 2009 Lasker-DeBakey Award for Clinical Medical Research for his work on Gleevec® (imatinib), including designing the first clinical trial for the targeted kinase inhibitor, which has transformed chronic myeloid leukemia (CML) from a fatal cancer into a manageable disease. Charles also played a key role in the development of Sprycel (dasatinib), another kinase inhibitor approved to treat CML. His laboratory is currently focused on characterizing signal transduction pathway abnormalities in prostate cancer. He is also building a program of lab-based translational researchers MSKCC as well as institutional infrastructure to enhance the application of genomics tools to clinical trials. Charles is past President of the American Society of Clinical Investigation and served on the National Cancer Institute’s Board of Scientific Councilors. He has won numerous honors and awards, including the Richard and Hinda Rosenthal Foundation Award, the Dorothy Landon Prize from the American Association of Cancer Research, the David A. Karnofsky Award from the American Society of Clinical Oncology and the 2013 Breakthrough Prize in Life Sciences. He is a member of the Institute of Medicine and was elected to the National Academy of Sciences in 2010. Charles has a bachelor’s degree from Princeton University, an MD from Johns Hopkins University School of Medicine and completed his postdoctoral studies at the University of California, Los Angeles.

Alice T. Shaw, M.D., Ph.D.

Associate Professor of Medicine at Harvard Medical School and Thoracic Oncologist at Massachusetts General Hospital

Alice is one of our scientific advisors. She is an oncologist at the Center for Thoracic Cancers at Massachusetts General Hospital (MGH) and an associate professor of medicine at Harvard Medical School. In addition to caring for patients with lung cancer, Alice performs clinical and translational research. Her major research interests include studying anaplastic lymphoma kinase (ALK) and ROS1 rearrangements in non-small cell lung cancer. She is also studying how lung cancers develop resistance to targeted therapies, and her work has led to a number of novel treatment strategies to overcome resistance in the clinic. Alice has been awarded a number of research grants, including grants from the Damon Runyon Cancer Research Foundation, the Burroughs Welcome Fund, the V Foundation for Cancer Research, Uniting Against Lung Cancer, the National Foundation for Cancer Research, and the NIH/NCI. She earned her M.D. at Harvard Medical School and her Ph.D. at Harvard University. She completed her residency at MGH and her fellowship at the Dana-Farber Cancer Institute.